“It is extremely exciting that LSU cardiology has been selected to be part
of the Underrepresented Registry of the Partners 3 Trial to study the safety
and efficacy of TAVR in low risk patients with severe aortic stenosis,” Dr.
Cox-Alomar says. “The study will be conducted in UMC. As we continue to
move down the risk spectrum, we are committed to providing exceptional
care without exception.”
